Clinical trials: Luminal B, open to volunteers
Breast Neoplasms, Triple Negative Breast Neoplasms
Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer
Breast cancer is the most common cancer in women worldwide. Its molecular classification, based on hormone receptors (estrogen and progesterone), HER2 and Ki-67, defines subtypes with different prognoses and treatments.
- Conditions
- Breast Neoplasms, Triple Negative Breast Neoplasms, HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer
- Trial name
- NCT07856225
- Testing
- CDK4/6 Inhibitors, Anti-HER2 Therapy, Standard Breast Cancer Treatment
- Where
- Colombia
- Volunteers
- 370 people
- Sponsor
- Fundación Santa Fe de Bogota
Breast Cancer Female
Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer
Patient derived xenografts (PDX) from mammary tumors are usually made from metastatic tumors. Indeed, PDX from primitive mammary tumors or after neoadjuvant treatment are still rare.
- Trial name
- XenoBreast (NCT04133077)
- Testing
- blood samples collection
- Where
- France
- Volunteers
- 85 people
- Sponsor
- Centre Jean Perrin
Breast Cancer, Radiotherapy
Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer
IBISCO TRIAL is a phase II trial aimed to demonstrate the improvement of pathological complete response (pCR) in Luminal B breast cancer (BC) patients treated with stereotactic radiation therapy (SBRT) as an anticipated boost…
- Trial name
- NCT05673304
- Testing
- SBRT anticipated boost
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Cancer
Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast Cancer Patients (PhActHealth Study)
PhActHealth is a multicenter randomized controlled trial enrolling women with newly diagnosed luminal B or triple-negative breast cancer (BC) who are candidates for neoadjuvant therapy.
- Trial name
- PhActHealth (NCT07776951)
- Testing
- Pre-habilitation exercise program
- Where
- 2 sites in Italy
- Volunteers
- 126 people
- Sponsor
- University of Milan
Breast Cancer
Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
To determine whether short-term pre-operative nivolumab either as monotherapy or in combination with low dose doxorubicin or novel IO combinations can induce immune activation in early BC.
- Trial name
- BELLINI (NCT03815890)
- Testing
- Nivolumab, Ipilimumab
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- The Netherlands Cancer Institute